Dr. Efstathios Karamanos, MD

Dr. Karamanos practices at Arrowhead Regional Medical Center in Colton, California, part of San Bernardino County.

Dr. Karamanos' NPI, 1861838260, was assigned on May 13, 2013. Dr. Karamanos graduated from University of Athens in 2010. Dr. Karamanos holds Illinois license 036154902.

Dr. Karamanos' primary practice is Arrowhead Regional Medical Center, at 400 North Pepper Avenue, Colton, CA 92324 in San Bernardino County. The practice phone is (909) 580-1000.

Dr. Karamanos' primary practice is Arrowhead Regional Medical Center in Colton, California, part of San Bernardino County. The medical group on file is Cal Med Physicians and Surgeons. Dmand AI also links Dr. Karamanos to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Karamanos practices. Vendor and product names are available with a free account.

Plastic and reconstructive surgery is Dr. Karamanos' primary specialty in the NPI Registry, under taxonomy code 2086S0122X. Dr. Karamanos is board certified in plastic surgery by the American Board of Plastic Surgery. Dmand AI has Dr. Karamanos' licenses on file in 5 states: Illinois, California, Michigan, Tennessee and Ohio.

Dmand AI lists breast reconstruction, breast surgery and cancerous skin growth removal among the conditions Dr. Karamanos treats.

CMS data shows 40 Medicare services from Dr. Karamanos across 2 procedure codes in 2024, all of them office visits, for 38 Medicare patients. Medicare paid $3,834 for them. Every service was in an office.

CMS counts 38 Medicare patients who saw Dr. Karamanos in 2024. The largest group is 65 to 74, with 17 patients. 75% of them have high cholesterol, and 74% have high blood pressure. Their average risk score is 1.20, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Karamanos' median patient age at 42, with 64% women.

In 2024, Dr. Karamanos wrote 83 Medicare Part D claims for 31 patients. 98% of them were for generic drugs. CMS names the drug for 36 of them, across 2 drugs with 11 or more claims each, at $239 in total drug cost. In 2023, CMS named 45 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 78 out of 100 for Dr. Karamanos for performance year 2024, reported as part of a group. Dr. Karamanos accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 47 papers to Dr. Karamanos, published from 2013 to 2024. 2020 was the busiest year, with 7. The most frequent topics are Postoperative Complications, Free Tissue Flaps and Mammaplasty. Dr. Karamanos has published most often in Plast Reconstr Surg Glob Open. Dr. Karamanos' most frequent co-authors are Howard T. Wang, MD, Noah H. Saad, MD and Nathan Schmoekel, DO.

CMS Open Payments shows 59 general payments to Dr. Karamanos from 17 drug and device companies from 2021 to 2025. Food and beverage make up the largest share, 52% of the total. TELA Bio, Inc. paid the most, $2,110.

Dr. Karamanos graduated from University of Athens in 2010.

Dr. Karamanos is in network with 11 carriers, including Aetna, Elevance and HCSC. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.